Asian Spine Journal

Inage, Orita, Yamauchi, Sakuma, Kubota, Oikawa, Sainoh, Sato, Fujimoto, Shiga, Takahashi, and Ohtori: Erratum: Correction of Figures. The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis

Erratum

Online first: December 08, 2015

DOI: https://doi.org/10.4184/asj.2015.9.6.999

Erratum: Correction of Figures. The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis

Kazuhide Inage¹, Sumihisa Orita¹, Kazuyo Yamauchi¹, Yoshihiro Sakuma², Go Kubota¹, Yasuhiro Oikawa³, Takeshi Sainoh¹, Jun Sato¹, Kazuki Fujimoto¹, Yasuhiro Shiga¹, Kazuhisa Takahashi¹, Seiji Ohtori¹

¹Department of Orthopedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

²Department of Orthopedic Surgery, National Hospital Organization Chiba Medical Center, Chiba, Japan.

³Department of Orthopedic Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.

(open-access, http://creativecommons.org/licenses/by-nc/3.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Asian Spine J 2015;9(3):338-343

http://dx.doi.org/10.4184/asj.2015.9.3.338

Corrections for Fig. 2, Fig. 3, and Fig. 4 in page 340 are needed.

There were some mistakes in the numerical values of the graphs. We apologize for any inconvenience that this may have caused.

• Before correction

Fig. 2. P1NP levels before and 1 month after administrating the anti-RANKL antibody. P1NP, N-terminal propeptide of type 1 collagen; RANKL, receptor activator of nuclear factor-kappa B ligand; NS, not significant.

• After correction

• Before correction

Fig. 3. The averages YAM level for the anti-RANKL antibody before and 6 months after treatment. YAM, young adult mean; RANKL, receptor activator of nuclear factor-kappa B ligand.

• After correction

Fig. 3. The averages YAM level for the anti-RANKL antibody before and 6 months after treatment. YAM, young adult mean; RANKL, receptor activator of nuclear factor-kappa B ligand.

• Before correction

Fig. 4. The time course changes by using the back pain VAS before treatment and 1, 2, 3, and 6 months after treatment. VAS, visual analogue scale; NS, not significant.

• After correction

Fig. 4. The time course changes by using the back pain VAS before treatment and 1, 2, 3, and 6 months after treatment. VAS, visual analogue scale; NS, not significant.